

**Sen-hong (Sen) Zhuang**, M.D. (Sun Yat-Sen University of Medical Sciences), Ph.D. (University of Miami School of Medicine), Residency (Long Island Jewish Medical Center), Hem/Onc fellowship (National Cancer Institute), vice president of the Clinical Oncology Research Program at Johnson & Johnson. Selected honor and leadership roles: the clinical head of the Hematology Disease Area Stronghold, leader for the global clinical development of YONDELIS (soft tissue sarcoma and ovarian cancer), DOXIL (multiple myeloma and breast cancer), ZARNESTRA (acute myelogenous leukemia and myelodysplastic syndrome), Senicapoc (sickle cell anemia), HDAC inhibitor, HDM-2 inhibitor, FGR Inhibitor programs, ZYTIGA and others. Area of focus: global clinical development of hematologic assets such as ibrutinib (IMBRUVICA) and daratumumab. Role: co-chair of the Industry Committee. E-mail: [szhuang1@its.jnj.com](mailto:szhuang1@its.jnj.com)